ArticleBMC pediatrics2025
Endoscopic retrograde cholangiopancreatography for the treatment of common bile duct dilatation with choledocholithiasis in children: a single-center retrospective cohort study of 58 cases.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Application of endoscopic retrograde cholangiopancreatography in children with common bile duct microdilation: a single-center retrospective cohort study of 36 cases.BMC pediatrics · 2025Article
- The application of gastrointestinal endoscopy in children: a narrative review.Frontiers in pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCongenital biliary dilatation (CBD) represents a prevalent congenital anomaly in pediatric surgery, with concurrent choledocholithiasis observed in a notable subset of pediatric patients. Improper management of such cases can compromise early diagnosis of CBD and adversely impact outcomes of radical surgery. This retrospective study evaluated the safety and efficacy of endoscopic retrograde cholangiopancreatography (ERCP) in pediatric patients with common bile duct dilatation complicated by choledocholithiasis, aiming to refine clinical strategies for diagnosis and preoperative management to mitigate long-term complications.
methodsA retrospective analysis was conducted on pediatric patients diagnosed with common bile duct dilatation and stones who underwent therapeutic ERCP at Wuhan Children's Hospital from August 2019 to July 2024. Clinical data, including demographic characteristics, laboratory tests, imaging findings, and ERCP-related parameters, were reviewed. Further subgroup analyses were performed based on the presence of postoperative adverse events and the coexistence of pancreaticobiliary maljunction (PBM).
resultsA total of 58 children with common bile duct dilatation and stones underwent 58 ERCP procedures, achieving a 100% procedural success rate. After ERCP, liver transaminase and bilirubin levels significantly decreased (P < 0.01). Postoperative follow-up showed a choledochal diameter of < 10 mm in 43 patients, with an overall effectiveness rate of 74.1% (n = 43/58). Among patients who did not undergo radical surgery (n = 48), the prognosis during follow-up (mean duration: 29.9 months) was favorable, and Likert scores were not associated with the presence of PBM (P > 0.05). The incidence of postoperative adverse events (n = 11/58, 19.0%) was significantly correlated with cannulation duration (P < 0.01). Patients in the PBM group (n = 21/58, 36.2%) were more likely to be female, younger, and have lower height and weight, with no differences found in other characteristics.
conclusionERCP is a safe and effective treatment for pediatric common bile duct dilatation with stones. Regardless of whether radical surgery was performed or the presence of PBM, patients showed improved laboratory parameters and symptom relief following ERCP. The effectiveness and incidence of adverse events were not related to PBM, but postoperative adverse events were associated with cannulation duration. Beyond its diagnostic utility in CBD and PBM, ERCP serves as a safe bridging therapy prior to radical surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.